Nivolumab in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma

Exclusion Criteria

• •All primary cutaneous T-cell lymphomas
• •Any of the following:
• •* Pregnant women
• •* Nursing women
• •* Men or women of childbearing potential who are unwilling to employ adequate contraception
• •Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens
• •Active, known or suspected autoimmune disease Note: subjects are permitted to enroll if they have vitiligo, type I diabetes mellitus, residual hypothyroidism due to autoimmune condition only requiring hormone replacement, psoriasis not requiring systemic treatment
• •Use of systemic treatment with either corticosteroids (\>10 mg daily prednisone equivalents) or other immunosuppressive medications \< 14 days of registration Note: inhaled or topical steroids are permitted; \> 10 mg daily prednisone equivalents are permitted only in adrenal insufficiency in the absence of active autoimmune disease
• •Prohibited treatments and or therapies
• •* Autologous stem cell transplant (ASCT) =\< 12 weeks prior to first dose of the study drug
• •* Prior treatments (window prior to registration):
• •* Chemotherapy =\< 2 weeks
• •* Nitrosureas =\< 6 weeks
• •* Therapeutic anticancer antibodies =\< 4 weeks
• •* Radio- or toxin immunoconjugates =\< 10 weeks
• •* Radiation therapy =\< 3 weeks
• •* Or major surgery =\< 2 weeks
• •* Prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CTLA-4 antibody, or any other antibody or drug specifically targeting T-cell costimulation or immune checkpoint pathways
• •* Prior allogeneic stem cell transplant (SCT)
• •* Chest radiation =\< 24 weeks prior to registration
• •Immunocompromised patients, patients with known history of testing positive for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS) and currently receiving antiretroviral therapy, active hepatitis B virus surface antigen (HBV sAg+), active hepatitis C (if Ab+ then PCR+) indicating acute or chronic infection
• •Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
• •Receiving any other investigational agent which would be considered as a treatment for the primary neoplasm
• •Other active malignancy =\< 3 years prior to registration EXCEPTIONS: non-melanotic skin cancer or carcinoma-in-situ of the cervix NOTE: if there is a history of prior malignancy, they must not be receiving other specific treatment for their cancer
• •Active central nervous system (CNS) involvement or leptomeningeal involvement
• •History of pancreatitis